Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Test Screens Source Plasma for HIV, Hepatitis B, and Hepatitis C Virus

By LabMedica International staff writers
Posted on 15 Dec 2009
A nucleic acid technology (NAT) test for screening plasma specimens can now be used to screen source plasma in pools comprised of up to 96 individual donations.

The cobas TaqScreen MPX test is a qualitative, in vitro test for the simultaneous, direct detection of the human immunodeficiency virus (HIV-1 Group M RNA, HIV-1 Group O RNA, HIV-2 RNA), hepatitis C virus (HCV) RNA, and hepatitis B virus (HBV) DNA in human plasma. More...
The MPX test runs on the fully automated, real-time Roche PCR cobas s 201 system, designed to increase processing efficiency with a unique modular design and ready-to-use reagents. The system has the capability of running multiple channels using multi-dye technology, enabling simultaneous detection of several viruses. The cobas TaqScreen MPX and the cobas s 201 system were developed by Roche (Basel, Switzerland). The test has been approved by the U.S. Food and Drug Administration (FDA), and it has received the European CE marking for screening source plasma. Roche is also developing another multi-dye assay on the same platform, the cobas TaqScreen DPX test, which is designed to provide simultaneously a quantitative result for B19 virus and a qualitative result for hepatitis A virus.

"As a standalone PCR system the cobas s 201 system and cobas TaqScreen MPX test for HBV, HIV, and HCV, provides a simple user interface while improving process control and lab efficiencies,” said Douglas Lee Sr., Ph.D., director of pathogen safety and research at Talecris Biotherapeutics (Research Triangle Park, NC, USA), one of the largest fractionators in the United States and a clinical trial site for the new test.

"Roche is committed to providing the broadest coverage and an easy-to-use menu of screening tests to ensure the highest safety of blood and plasma products,” said Daniel O'Day, head of Roche Molecular Diagnostics. "The expanded use of our multiplex test, which has been widely adopted and has demonstrated excellent performance worldwide, is one more step toward that goal.”

Many countries have implemented NAT testing in order to ensure further the safety of blood and blood products. In Western Europe and North America, routine NAT testing, which can detect HIV-1 and HCV in the early stages of infection, has reduced the risk of transfusion-transmitted infections to negligible levels. The importance of HBV in transfusion-transmitted diseases is increasingly being recognized and NAT screening for HBV is now being implemented in some countries.

Related Links:

Roche
Talecris Biotherapeutics



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Hemodynamic System Monitor
OptoMonitor
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.